Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnologist Oncolytics Biotech (NASDAQ:ONCY) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Oncolytics and see what CAPS investors are saying about the stock right now.

Oncolytics facts

Headquarters (founded)

Calgary, Canada (1998)

Market Cap

$169.5 million

Industry

Biotechnology

Trailing-12-Month EBITDA

($40.2 million)

Management

Chairman/CEO Bradley Thompson
CFO Kirk Look

Return on Equity (average, past 3 years)

(124.2%)

Cash/Debt

$28.5 million / $0

Competitors

GlaxoSmithKline (NYSE:GSK)Infinity Pharmaceuticals (NASDAQ:INFI)Medivation (NASDAQ:MDVN)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 25% of the 87 members who have rated Oncolytics believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock's recent bounce as particularly unsustainable:

I'm fairly confident that Reolysin is inactive, so I'll take any excuse to red thumb Oncolytics until it eventually goes to zero. I missed the lion's share of the decline but there's been no good news to explain the recent change in momentum. I suspect a fresh round of dilution will come before any significant data release from ongoing Reolysin trials.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.